Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.25.2
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
6 Months Ended
Jun. 30, 2025
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended June 30,

​

Six-Month Periods Ended June 30,

($ in thousands)

    

2025

    

2024

    

2025

    

2024

EmrosiTM

​

$

2,795

​

$

—

​

$

4,865

​

$

—

Qbrexza®

​

​

6,949

​

​

6,836

​

​

12,110

​

​

11,853

Accutane®

​

 

3,395

​

 

5,719

​

 

7,050

​

 

11,538

Amzeeq®

​

​

879

​

​

1,205

​

​

1,979

​

​

1,960

Zilxi®

​

​

256

​

​

369

​

​

682

​

​

642

Other / legacy

​

​

735

​

​

726

​

​

1,462

​

​

1,892

Total product revenues

​

$

15,009

​

$

14,855

​

$

28,148

​

$

27,885